Compare UTF & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UTF | NAMS |
|---|---|---|
| Founded | N/A | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | 100 |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.3B |
| IPO Year | 2004 | N/A |
| Metric | UTF | NAMS |
|---|---|---|
| Price | $26.98 | $38.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $46.75 |
| AVG Volume (30 Days) | 295.3K | ★ 938.9K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $17.96 |
| Revenue Next Year | N/A | $540.65 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.42 | $16.79 |
| 52 Week High | $27.35 | $42.00 |
| Indicator | UTF | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 60.91 | 69.61 |
| Support Level | $26.65 | $34.05 |
| Resistance Level | $27.17 | $41.40 |
| Average True Range (ATR) | 0.34 | 2.20 |
| MACD | 0.04 | 0.62 |
| Stochastic Oscillator | 74.07 | 77.33 |
Cohen & Steers Infrastructure Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is total return with an emphasis on income. Under normal market conditions, the fund invests the majority of its managed assets in securities issued by infrastructure companies, which consist of utilities, pipelines, toll roads, airports, railroads, ports, telecommunications companies, and other infrastructure companies.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.